Droperidol Side Effects
Some side effects of droperidol may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to droperidol: injection injectable, injection solution
Along with its needed effects, droperidol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur while taking droperidol:Less common
- high blood pressure
- fixed upward position of the eyeballs
- irregular or slow heart rate
- spasm of the muscles of the tongue, face, neck, and back
- sudden death
For Healthcare Professionals
Applies to droperidol: compounding powder, injectable solution
Cardiovascular side effects including cases of QT prolongation, serious arrhythmias (e.g., torsades de pointes), ventricular tachycardia, and cardiac arrest have been reported. Some of these side effects were associated with death. Some of these side effects occurred in patients with no known risk factors, and some were associated with droperidol doses at or below recommended doses. Hypotension and mild to moderate tachycardia have been the most commonly reported somatic adverse events.
A 60-year-old male with no history of cardiac disease experienced ventricular tachycardia leading to coronary artery spasm coincident with droperidol therapy. The patient underwent ileocecectomy to treat ileocecal lymphoma. One and one half hour after the start of surgery, he was given droperidol 1 mg intravenous as prophylaxis for postoperative nausea and vomiting. Within a few minutes, he developed ventricular fibrillation with a torsades de pointes pattern, which subsided after electrical cardioversion. Subsequent monitoring revealed ST segment depression. Twelve-lead electrocardiogram approximately 5 minutes after defibrillation revealed slight ST segment elevation in the inferior limb leads, and increased QTc of 463 ms. The ST segment elevation returned to baseline after several minutes. On day 5 after surgery, the patient underwent cardiac catherization. Coronary angiograms revealed no significant stenosis, but intracoronary injection of 10 mcg ergonovine maleate provoked total obstruction of the middle right coronary artery segment, accompanied by inferior ST segment elevations and polymorphic premature ventricular contractions.
Nervous system side effects including dysphoria, drowsiness, restlessness, hyperactivity, and anxiety have been the most commonly reported behavioral effects. Hallucinations, dizziness, pain, confusion, nervousness, paresthesia, somnolence, tremor, and neuroleptic malignant syndrome have been reported. Extrapyramidal symptoms such as acute dystonia, parkinsonism, akathisia, and oculogyric crisis have been reported in patients receiving droperidol in doses as low as 0.65 mg. In addition, cases of akathisia have been reported in patients during epidural anesthesia. Unexplained fever, alteration of consciousness, extrapyramidal dysfunction, autonomic instability, and elevated creatine kinase have been reported with neuroleptic agents.
Respiratory side effects have included pharyngitis and rhinitis. Bronchospasm and laryngospasm have been less commonly reported.
Hypersensitivity side effects including cases of anaphylaxis have been reported.
Gastrointestinal side effects including sialorrhea, nausea, dry mouth, and anorexia have been reported.
Local side effects including injection site pain and reaction have been reported.
Other side effects including chills and/or shivering and tongue-swelling have been reported occasionally. Asthenia and sweating have also been reported.
More droperidol resources
- droperidol MedFacts Consumer Leaflet (Wolters Kluwer)
- droperidol Concise Consumer Information (Cerner Multum)
- droperidol Injection Advanced Consumer (Micromedex) - Includes Dosage Information
- Droperidol Prescribing Information (FDA)
- Droperidol Professional Patient Advice (Wolters Kluwer)
- Droperidol Monograph (AHFS DI)
- Inapsine Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.